Thu, Jul 10, 2014, 12:26 AM EDT - U.S. Markets open in 9 hrs 4 mins

Recent

% | $
Quotes you view appear here for quick access.

Ironwood Pharmaceuticals, Inc. Message Board

  • big_pharma_coming big_pharma_coming Aug 30, 2012 3:01 PM Flag

    JPM "Best case approval - no gender or duration limitations. Blockbuster potential. Reiterate Overweight". $21 target. Bst

    JP MORGAN
    August 30, 2012

    Ironwood Pharmaceuticals
    Overweight
    Target $21

    Ironwood announced the approval of Linzess (linaclotide) for the treatment of both irritable bowel syndrome constipation (IBS-C) and chronic constipation. The approval comes as no surprise to us given the robust phase 3 data set in both indications. Recall, the PDUFA for linaclotide had been delayed by 3 months previously (from June to September) so the agency could better understand potential differences between doses in the CC trials (145mcg/d and 290mcg/d). This, coupled with initiation of an additional phase 3 trial in CC, did raise fears of approval only in the IBS-C indication, which did not happen. Of note, the 290mcg/d dose was not approved in CC, but we do not view this as a major set back. Importantly, based on the FDA press release, there does not appear to be any limitations on gender or duration of therapy (a best case). Looking forward, we expect full commercial launch by YE12. Given the unmet need in IBS-C / CC, we believe our and consensus 2013 Linzess estimates could prove conservative (2013 – cons: $153M; JPMe: $131M), despite the broad physician audience (PCPs and GIs) which Ironwood and partner Forest will have to market too (covered by J.P. Morgan analyst Chris Schott). We are reiterating our Overweight rating on IRWD shares.

    Full commercial launch expected by YE12: Recall, Ironwood / Forest will finalize label / materials and Linzess will undergo a short “scientific launch.” This process is expected to take about 3 months. Given the large physician audience for Linzess, we believe it is prudent that Ironwood / Forest will be gathering physician feedback, etc., over the next several months, so to optimize the full commercial launch.

    Market potential of linaclotide: We estimate 2015 worldwide Linzess sales of ~$750M and anticipate the drug reaches blockbuster potential in 2016. Our pricing assumption as of right now is $6/day (increasing price and duration of therapy overtime).

    Reiterate Overweight

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • JP MORGAN
      August 30, 2012

      Ironwood Pharmaceuticals
      Overweight
      Target $21

      Ironwood announced the approval of Linzess (linaclotide) for the treatment of both irritable bowel syndrome constipation (IBS-C) and chronic constipation. The approval comes as no surprise to us given the robust phase 3 data set in both indications. Recall, the PDUFA for linaclotide had been delayed by 3 months previously (from June to September) so the agency could better understand potential differences between doses in the CC trials (145mcg/d and 290mcg/d). This, coupled with initiation of an additional phase 3 trial in CC, did raise fears of approval only in the IBS-C indication, which did not happen. Of note, the 290mcg/d dose was not approved in CC, but we do not view this as a major set back. Importantly, based on the FDA press release, there does not appear to be any limitations on gender or duration of therapy (a best case). Looking forward, we expect full commercial launch by YE12. Given the unmet need in IBS-C / CC, we believe our and consensus 2013 Linzess estimates could prove conservative (2013 – cons: $153M; JPMe: $131M), despite the broad physician audience (PCPs and GIs) which Ironwood and partner Forest will have to market too (covered by J.P. Morgan analyst Chris Schott). We are reiterating our Overweight rating on IRWD shares.

      Full commercial launch expected by YE12: Recall, Ironwood / Forest will finalize label / materials and Linzess will undergo a short “scientific launch.” This process is expected to take about 3 months. Given the large physician audience for Linzess, we believe it is prudent that Ironwood / Forest will be gathering physician feedback, etc., over the next several months, so to optimize the full commercial launch.

      Market potential of linaclotide: We estimate 2015 worldwide Linzess sales of ~$750M and anticipate the drug reaches blockbuster potential in 2016. Our pricing assumption as of right now is $6/day (increasing price and duration of therapy overtime).

      Reiterate Overweight

      Sentiment: Strong Buy

    • Expect JP Morgan and Morgan Stanley to raise targets in a day or so

 
IRWD
14.39+0.22(+1.55%)Jul 9 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.